Reporter brief
RCT of rapamycin in older adults: study design and rationale, no results reported
What happened
This was a randomized controlled trial proposed to test whether rapamycin (sirolimus) could slow aging processes and reduce biomarkers of aging in older adults. The abstract describes the study design, theoretical rationale based on mTOR pathway inhibition, and stated hypothesis that rapamycin may impact aging and chronic disease development. No results, sample size, or effect measures are reported.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Older adults
- Design
- Rct
- Sample
- —
- Journal
- NOT_REPORTED
- Published
- Jun 25, 2026
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.